Semaglutide Launch: Domestic companies launch semaglutide jabs at affordable prices & more related News Here

This comes in the wake of innovator Novo Nordisk losing its patent on semaglutide on March 20.Sun Pharma’s weekly therapy cost, from starting to highest dose, ranges from approximately Rs 900 to Rs 2,000 for NovelaTreat and Rs 750 to Rs 1,300 for Semtrinity, supporting greater affordability, the company said in a statement.“To further support patients, we are also launching a holistic patient assistance program that aims to guide them throughout their treatment journey,” said Kirti Ganorkar, Managing Director, Sun Pharma.Additionally, Torrent Pharma has launched both oral and injectable formulations, expanding its presence in metabolic disorders such as Type-2 diabetes and obesity. Amal Kelshikar, CEO – India Business, Torrent Pharma, said, “We are proud to be the first Indian company to offer this treatment in oral and injectable formulations, providing healthcare professionals with a holistic option to treat patients.”Others like USV announced launches in collaboration with Dr. Reddy’s Labs. The flurry of launches reflects a broader effort by companies to capture India’s fast-growing metabolic disorders market.Blockbuster weight-loss therapies – Vegovi and Monjaro – marketed by Novo Nordisk and Eli Lilly respectively, were launched last year at ”India-specific prices”, while global bestseller Ozempic by the Dutch firm had made its India debut only in December last year. Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, helps control blood sugar and improve satiety, reducing cravings for food, ultimately inducing weight loss.These launches come as India faces a rising burden of diabetes, with more than 100 million people currently suffering from diabetes.